An application for marketing authorization of a new drug developed by Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (ASX: 600276) has been formally accepted for review by the European Medicines Agency (EMA).
This marks the first time the company's own independently researched and developed innovative drug has been submitted for approval within the European Union.
The drug in question, Rezvilutamide tablets, is intended for use in combination with androgen deprivation therapy (ADT) to treat adult male patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments